Commentary on research to improve contraceptive and multipurpose prevention technologies
Document Type
Commentary
Publication Date
3-5-2020
Abstract
The development of innovative fertility regulation technologies requires multi-sectoral expertise: biology and biochemistry; engineering; clinical trial research; regulatory approval; manufacturing; and mechanisms to ensure that safe, acceptable, and effective products reach interested users. This requires substantial and diverse investments and often requires decades of commitment. However, since at least 1990, experts have noted significant underinvestment in new contraceptive technologies. Compared to other health technologies, the high costs and risks associated with the development and introduction of new contraceptives make such investments less attractive to the pharmaceutical industry and other prospective investors.
Recommended Citation
Speidel, J. Joseph, John Townsend, Elspeth Williams, Jamie Quam, and Kirsten M.J. Thompson. 2020. "Commentary on research to improve contraceptive and multipurpose prevention technologies," Contraception 101(3): 148–152.
DOI
10.1016/j.contraception.2019.12.005
Language
English